BACKGROUND: The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment. METHODS: We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive. RESULTS: The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (<or=4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors. CONCLUSIONS: Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.
BACKGROUND: The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment. METHODS: We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLCpatients initially presented with limited disease, while 92 small cell lung carcinomapatients were found to be extensive. RESULTS: The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (<or=4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors. CONCLUSIONS: Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLCpatients.
Authors: M Paesmans; J P Sculier; J Lecomte; J Thiriaux; P Libert; R Sergysels; G Bureau; G Dabouis; O Van Cutsem; P Mommen; V Ninane; J Klastersky Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: U Sagman; E Maki; W K Evans; D Warr; F A Shepherd; J P Sculier; R Haddad; D Payne; J F Pringle; J L Yeoh Journal: J Clin Oncol Date: 1991-09 Impact factor: 44.544
Authors: C Christodolou; N Pavlidis; E Samantas; G Fountzilas; G Kouvatseas; K Pagdatoglou; F Palamidas; C Nikolaidis; M Angelidou; H P Kalofonos; P Kosmidis; D V Skarlos Journal: Anticancer Res Date: 2002 Nov-Dec Impact factor: 2.480
Authors: Xiaoling Chen; Jian Fang; Jun Nie; Ling Dai; Jie Zhang; Weiheng Hu; Jindi Han; Xiangjuan Ma; Guangming Tian; Sen Han; Di Wu; Jieran Long; Yang Wang Journal: Zhongguo Fei Ai Za Zhi Date: 2014-01